Amedica Corp launched its IPO after having priced its offering of 3.5 million shares at $5.75 per share. The stock began trading Thursday, February 20, 2014 on the NASDAQ under the ticker symbol “AMDA.” JMP Securities is the lead underwriter. Based in Salt Lake City, Amedica Corp is a provider of spinal and orthopedic implants. Its backers include GE Capital and Creation Capital.
Salt Lake City, UT, February 13, 2014 – Amedica Corporation (NASDAQ: AMDA) announced the pricing of its initial public offering of 3,500,000 shares of common stock at a public offering price of $5.75 per share. In addition, Amedica has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock from Amedica at the public offering price, less underwriting discounts. The offering is expected to close on February 19, 2014, subject to customary closing conditions. Amedica’s common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the ticker symbol “AMDA”.
JMP Securities LLC is acting as the sole book-running manager for the offering. Needham & Company, LLC is acting as co-manager for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 12, 2014. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from JMP Securities LLC by mail at JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, or by phone at (415) 835-8985, or from Needham & Company, LLC by mail at Needham & Company, LLC, 445 Park Avenue, 3rd Floor, New York, NY 10022, by email firstname.lastname@example.org, or by phone at (800) 903-3268.
About Amedica Corporation
Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica markets spinal fusion products and is developing product candidates for use in total hip and knee joint replacements. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and are currently marketed in the U.S. and in select markets in Europe and South America. Amedica is based in Salt Lake City, Utah.
Publised at - Amedica